ID   PRG-3/293T-Rex
AC   CVCL_C4CU
DR   Wikidata; Q116050127
RX   Patent=US20100111851;
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:25993; PLPPR1.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00722; Escherichia coli beta-galactosidase (lacZ).
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) (HygR).
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P04483; Escherichia coli Tn10 tetR.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR).
CC   Transformant: NCBI_TaxID; 28285; Adenovirus 5.
CC   Derived from site: In situ; Fetal kidney; UBERON=UBERON_0002113.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_U427 ! Flp-In-T-REx-293
SX   Female
AG   Fetus
CA   Transformed cell line
DT   Created: 15-12-22; Last updated: 10-04-25; Version: 7
//
RX   Patent=US20100111851;
RA   Aburatani H., Torisu Y., Funahashi S.-i.;
RT   "Diagnosis and treatment of cancer by using anti-PRG-3 antibody.";
RL   Patent number US20100111851, 06-May-2010.
//